GLP-1 and energy balance: an integrated model of short-term and long-term control

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature Reviews Endocrinology

• Publication date

  2011-06-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrendo.2011.77PMID 21647189PMCID PMC4231434
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hyperphagia and Increased Fat Accumulation in Two Models of Chronic CNS Glucagon-Like Peptide-1 Loss of Function

  2011cited by this paper
• Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

  2011cited by this paper
• Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.

  2010cited by this paper
• Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor.

  2010cited by this paper
• Molecular mechanisms underlying nutrient-stimulated incretin secretion

  2010cited by this paper
• Twelve weeks treatment with the DPP‐4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non‐glucose induced insulin secretion in patients with type 2 diabetes mellitus

  2010cited by this paper
• GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats.

  2010cited by this paper
• Incretin-based therapies: review of current clinical trial data.

  2010cited by this paper
• Leptin Directly Depolarizes Preproglucagon Neurons in the Nucleus Tractus Solitarius

  2010cited by this paper
• Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist.

  2010cited by this paper
• Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system.

  2010cited by this paper
• Sensitivity to the satiating effects of Exendin 4 is decreased in obesity-prone Osborne-Mendel rats compared to obesity-resistant S5B/Pl rats

  2010cited by this paper
• Meal-anticipatory glucagon-like peptide-1 secretion in rats.

  2010cited by this paper
• Glucocorticoid regulation of preproglucagon transcription and RNA stability during stress

  2009cited by this paper
• The effects of GLP-1 infusion in the hepatic portal region on food intake.

  2009cited by this paper
• Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms.

  2009cited by this paper
• Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.

  2009cited by this paper
• Hindbrain leptin receptor stimulation enhances the anorexic response to cholecystokinin.

  2009cited by this paper
• Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling.

  2009cited by this paper
• Direct Control of Peripheral Lipid Deposition by CNS GLP-1 Receptor Signaling Is Mediated by the Sympathetic Nervous System and Blunted in Diet-Induced Obesity

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Do Incretins Play a Role in the Remission of Type 2 Diabetes after Gastric Bypass Surgery: What are the Evidence?

  2009cited by this paper
• Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats

  2009cited by this paper
• Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

  2009cited by this paper
• Immune challenge and satiety-related activation of both distinct and overlapping neuronal populations in the brainstem indicate parallel pathways for viscerosensory signaling.

  2009cited by this paper
• Receptor‐mediated activation of gastric vagal afferents by glucagon‐like peptide‐1 in the rat

  2009cited by this paper
• Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite.

  2008cited by this paper
• Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes *

  2008cited by this paper
• Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients

  2008cited by this paper
• An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.

  2008cited by this paper
• Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control

  2008cited by this paper
• Arcuate Glucagon-Like Peptide 1 Receptors Regulate Glucose Homeostasis but Not Food Intake

  2008cited by this paper
• Upregulation of the brainstem preproglucagon system in the obese Zucker rat.

  2008cited by this paper
• Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.

  2008cited by this paper
• Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity

  2008cited by this paper
• Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat–Fed Mice

  2008cited by this paper
• Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation.

  2008cited by this paper
• Divergent leptin signaling in proglucagon neurons of the nucleus of the solitary tract in mice and rats.

  2008cited by this paper
• Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing

  2008cited by this paper
• Gastrointestinal satiety signals.

  2008cited by this paper
• Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons.

  2007cited by this paper
• The physiology of glucagon-like peptide 1.

  2007cited by this paper
• Glucagon-like peptide-1 modulates synaptic transmission to identified pancreas-projecting vagal motoneurons.

  2007cited by this paper
• Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei.

  2007cited by this paper
• Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.

  2007cited by this paper
• Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats.

  2007cited by this paper
• Biology of incretins: GLP-1 and GIP.

  2007cited by this paper
• Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.

  2007cited by this paper
• Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not

  2007cited by this paper
• The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size.

  2007cited by this paper
• Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats.

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

  2006cited by this paper
• Leptin Regulation of the Anorexic Response to Glucagon-Like Peptide-1 Receptor Stimulation

  2006cited by this paper
• Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

  2006cited by this paper
• Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures

  2006cited by this paper
• The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway.

  2005cited by this paper
• Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Leptin action in the forebrain regulates the hindbrain response to satiety signals.

  2005cited by this paper
• Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice.

  2005cited by this paper
• Insulin and leptin as adiposity signals.

  2004cited by this paper
• Insulin and leptin as adiposity signals.

  2004cited by this paper
• Attenuation of lipopolysaccharide anorexia by antagonism of caudal brain stem but not forebrain GLP-1-R.

  2004cited by this paper
• A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

  2004cited by this paper
• Gastrointestinal satiety signals II. Cholecystokinin.

  2004cited by this paper
• Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells.

  2004cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons.

  2003cited by this paper
• Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

  2003cited by this paper
• Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats.

  2003cited by this paper
• CNS Glucagon-Like Peptide-1 Receptors Mediate Endocrine and Anxiety Responses to Interoceptive and Psychogenic Stressors

  2003cited by this paper
• Role of leptin in the regulation of glucagon-like peptide-1 secretion.

  2003cited by this paper
• Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites

  2003cited by this paper
• Entry of exendin-4 into brain is rapid but may be limited at high doses

  2003cited by this paper
• The Diverse Roles of Specific GLP-1 Receptors in the Control of Food Intake and the Response to Visceral Illness

  2002cited by this paper
• Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.

  2002cited by this paper
• Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4.

  2002cited by this paper
• Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

  2001cited by this paper
• Is parental control over children's eating associated with childhood obesity? Results from a population-based sample of third graders.

  2001cited by this paper
• The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

  2001cited by this paper
• A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

  2001cited by this paper
• Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA.

  2000cited by this paper
• Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.

  2000cited by this paper
• Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats.

  2000cited by this paper
• Chemical characterization of leptin‐activated neurons in the rat brain

  2000cited by this paper
• The Role of CNS Glucagon-Like Peptide-1 (7-36) Amide Receptors in Mediating the Visceral Illness Effects of Lithium Chloride

  2000cited by this paper
• Antagonism of central glucagon-like peptide-1 receptors enhances lipopolysaccharide-induced fever.

  2000cited by this paper
• Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.

  2000cited by this paper
• Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats.

  2000cited by this paper
• Distribution of pre‐pro‐glucagon and glucagon‐like peptide‐1 receptor messenger RNAs in the rat central nervous system

  1999cited by this paper
• Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus.

  1999cited by this paper
• Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

  1999cited by this paper
• Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus.

  1999cited by this paper
• Central leptin modulates behavioral and neural responsivity to CCK.

  1999cited by this paper
• No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man

  1999cited by this paper
• Glucagon-like peptide-1: a potent regulator of food intake in humans

  1999cited by this paper
• Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.

  1999cited by this paper
• Repeated Intracerebroventricular Administration of Glucagon-Like Peptide-1-(7-36) Amide or Exendin-(9-39) Alters Body Weight in the Rat* *This work was supported by the United Kingdom Medical Research Council.

  1999cited by this paper

• Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

  2025cites this paper
• Daily profiles of plasma short-chain fatty acids after the intake of three different cereal fibers: a randomized controlled study

  2025cites this paper
• Current understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists

  2025cites this paper
• Polygonatum cyrtonema polysaccharide alleviates dopaminergic neuron apoptosis in Parkinson's disease mouse model via inhibiting oxidative stress and endoplasmic reticulum stress.

  2025cites this paper
• Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data

  2025cites this paper
• Weight loss injections for the obese and unemployed in the UK: is wellbeing the missing link?

  2025cites this paper
• May Patients Receiving GLP-1 Agonists Be at Lower Risk of Prostate Cancer Aggressiveness and Progression?

  2025cites this paper
• Brainstem GLP-1 neurons modulate physiological satiation and drive sustained weight loss in obese mice

  2025cites this paper
• Chayote pectin regulates blood glucose through the gut-liver axis: Gut microbes/SCFAs/FoxO1 signaling pathways.

  2025cites this paper
• Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss

  2025cites this paper
• Depletion of myeloid-derived Zbtb46+ cells improves glycemic control in obesity via the DPP4/GLP-1 pathway.

  2025cites this paper
• Advances in resistant starch: mechanisms, applications, and challenges in obesity management and low-fat food development.

  2025cites this paper
• Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis

  2025cites this paper
• GPCR Biased Signaling in Metabolism.

  2025cites this paper
• Satiety: a gut–brain–relationship

  2024cites this paper
• Systemic Co-Administration of Low-Dose Oxytocin and Glucagon-Like Peptide 1 Additively Decreases Food Intake and Body Weight

  2024cites this paper
• GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

  2024cites this paper
• Intestinal-level anti-inflammatory bioactivities of whole wheat: Rationale, design, and methods of a randomized, controlled, crossover dietary trial in adults with prediabetes.

  2024cites this paper
• The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury

  2024cites this paper
• Dietary β-mannanase supplementation decreases digesta viscosity, improves growth and modulates gut microbiota in juvenile Nile tilapia, Oreochromis niloticus fed a soybean meal-based diet

  2024cites this paper
• Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity

  2024cites this paper
• Dichotomous effect of dietary fiber in pediatrics: a narrative review of the health benefits and tolerance of fiber

  2024cites this paper
• The Emerging Role of GLP-1 Agonists in Burn Care: What Do We Know?

  2024cites this paper
• Effects of a diverse prebiotic fibre supplement on HbA1c, insulin sensitivity and inflammatory biomarkers in pre-diabetes: a pilot placebo-controlled randomised clinical trial

  2024cites this paper
• TorS ‐ Reframing a rational for type 2 diabetes treatment

  2023cites this paper
• Perspectives in weight control in diabetes - BI 456906.

  2023cites this paper
• Germinated and non-germinated cooked whole millet (Pennisetum glaucum (L.) R. Br.) flours show a promising effect on protein quality, biochemical profile and intestinal health in vivo.

  2023cites this paper
• Real-Life Efficacy of Liraglutide Therapy on Weight-Loss in Patients with Overweight and Obesity

  2023cites this paper
• GDF15 is a major determinant of ketogenic diet-induced weight loss.

  2023cites this paper
• Pectin mediates the mechanism of host blood glucose regulation through intestinal flora

  2023cites this paper
• Interaction between genetics and inulin affects host metabolism in rainbow trout fed a sustainable all plant-based diet

  2023cites this paper
• Gut–vagus–NTS neural pathway in controlling feeding behaviors

  2023cites this paper
• Contribution of the microbiome for better phenotyping of people living with obesity

  2023cites this paper
• The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission

  2023cites this paper
• Gut HIF2α signaling is increased after VSG, and gut activation of HIF2α decreases weight, improves glucose, and increases GLP-1 secretion

  2022cites this paper
• Reviewing the physiological roles of the novel hormone-receptor pair INSL5-RXFP4: a protective energy sensor?

  2022cites this paper
• A Self-Powered Optogenetic System for Implantable Blood Glucose Control

  2022cites this paper
• Association of age and body condition with physical activity of domestic cats (Felis catus)

  2022cites this paper
• Single-Cell Analysis Reveals Unexpected Cellular Changes and Transposon Expression Signatures in the Colonic Epithelium of Treatment-Naïve Adult Crohn’s Disease Patients

  2022cites this paper
• The Role of Gut Microbiota and Metabolites in Obesity-Associated Chronic Gastrointestinal Disorders

  2022cites this paper
• Research_9864734 1..13

  2022cites this paper
• Action mechanism of hypoglycemic principle 9-(R)-HODE isolated from cortex lycii based on a metabolomics approach

  2022cites this paper
• Integrative biology of extracellular vesicles in diabetes mellitus and diabetic complications

  2022influential citation
• Altered chronic glycemic control in a clinically relevant model of rat thoracic spinal contusion

  2022cites this paper
• AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE

  2022cites this paper
• Involvement of Peripheral Opioid Receptors in the Realization of Food Motivation Into Eating Behavior

  2021cites this paper
• Effect of Dietary Acetic Acid Supplementation on Plasma Glucose, Lipid Profiles, and Body Mass Index in Human Adults: A Systematic Review and Meta-analysis.

  2021cites this paper
• The deletion of glucagon-like peptide-1 receptors expressing neurons in the dorsomedial hypothalamic nucleus disrupts the diurnal feeding pattern and induces hyperphagia and obesity

  2021cites this paper
• Plasma levels of ghrelin and GLP-1, but not leptin or amylin, respond to a psychosocial stressor in women and men.

  2021cites this paper
• A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management

  2021cites this paper
• Post-oral sensing of fat increases food intake and attenuates body weight defense.

  2021cites this paper
• Activation of PPG neurons following acute stressors differentially involves hindbrain serotonin in male rats.

  2021cites this paper
• Single-cell analysis of colonic epithelium reveals unexpected shifts in cellular composition and molecular phenotype in treatment-naïve adult Crohn’s disease

  2021cites this paper
• Fluid intake, what's dopamine got to do with it?

  2021cites this paper
• Comprehensive Review of Current and Upcoming Anti-Obesity Drugs

  2020cites this paper
• Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress

  2020cites this paper
• Glucagon-like peptide-1 receptors modulate the binge-like feeding induced by µ-opioid receptor stimulation of the nucleus accumbens in the rat

  2020cites this paper
• Functional interaction between Ghrelin and GLP-1 regulates feeding through the vagal afferent system

  2020cites this paper
• The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin.

  2020cites this paper
• Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis

  2020cites this paper
• Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function.

  2020cites this paper
• Adropin and apelin‐12 efficiently predict metabolic syndrome in obese children

  2020cites this paper
• Health Effects of Short‐Chain, Medium‐Chain, and Long‐Chain Fatty Acids, Saturated Vs Unsaturated and Omega‐6 Vs Omega‐3 Fatty Acids and Trans Fats

  2020cites this paper
• Relationship between inflammation and metabolic regulation of energy expenditure by GLP-1 in critically ill children.

  2020cites this paper
• Short-Chain Fatty Acids and Their Association with Signalling Pathways in Inflammation, Glucose and Lipid Metabolism

  2020cites this paper
• Diabetes, and its treatment, as an effector of autonomic nervous system circuits and its functions.

  2020cites this paper
• Adropin and Apelin -12, two better predictors of metabolic syndrome in obese children

  2020cites this paper
• Carcinoembryonic Cell Adhesion-Related Molecule 2 Regulates Insulin Secretion and Energy Balance

  2019cites this paper
• The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1

  2019cites this paper
• Hypophagia induced by hindbrain serotonin is mediated through central GLP-1 signaling and involves 5-HT2C and 5-HT3 receptor activation

  2019cites this paper
• Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity

  2019cites this paper
• The relationship between enteral nutrition, energy metabolism and gut homeostasis during the course of critical illness

  2019cites this paper
• Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties.

  2019cites this paper
• Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes.

  2019cites this paper
• Effects of Fasting on Glucagon-like peptide-1 hormone (GLP-1), and Lipid Profile Indices in Obese and Thin Women

  2019cites this paper
• Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.

  2018cites this paper
• Effect of different surgical weight-loss interventions and ethnicity on GLP-1 secretion

  2018influential citation
• Emerging therapeutic potential for peptide YY for obesity‐diabetes

  2018cites this paper
• Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice

  2018cites this paper
• Effects of dietary short- and medium-chain fatty acids on performance, carcass traits, jejunum morphology, and serum parameters of broiler chickens

  2018cites this paper
• Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial

  2018cites this paper
• Mechanisms Underlying Host-Microbiome Interactions in Pathophysiology of Human Diseases

  2018cites this paper
• Optogenetic Medicine: Synthetic Therapeutic Solutions Precision-Guided by Light.

  2018cites this paper
• A polyphenol-rich prebiotic in combination with a novel probiotic formulation alleviates markers of obesity and diabetes in Drosophila

  2018cites this paper
• GLP‐1 suppresses glucagon secretion in human pancreatic alpha‐cells by inhibition of P/Q‐type Ca2+ channels

  2018cites this paper
• Аналог глюкагоноподобного пептида-1 лираглутид (Саксенда®): механизм действия, эффективность в лечении ожирения

  2018cites this paper
• Interventions for the Treatment of Craniopharyngioma-Related Hypothalamic Obesity: A Systematic Review.

  2018cites this paper
• Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β3-Adrenergic Receptor Agonist

  2018cites this paper
• Plasma Adropin as a Potential Marker Predicting Obesity and Obesity-associated Cancer in Korean Patients With Type 2 Diabetes Mellitus

  2018cites this paper
• Corrigendum: Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides

  2018cites this paper
• Alfalfa-containing diets alter luminal microbiota structure and short chain fatty acid sensing in the caecal mucosa of pigs

  2018cites this paper
• Battle of GLP-1 delivery technologies.

  2018cites this paper
• Gastrointestinal Hormones Controlling Energy Homeostasis and Their Potential Role in Obesity

  2018cites this paper
• Considering our methods: Methodological issues with rodent models of appetite and obesity research.

  2018cites this paper
• Altered Microbiota and Their Metabolism in Host Metabolic Diseases

  2018cites this paper
• GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis

  2017cites this paper
• Novel biomarkers associated with gestational diabetes mellitus and metabolic outcomes of pregnancy

  2017cites this paper
• Gut-Brain Cross-Talk in Metabolic Control.

  2017cites this paper
• A Role for CEACAM2 protein in Insulin Secretion, Clearance and Action

  2017cites this paper
• Just a Gut Feeling: Central Nervous Effects of Peripheral Gastrointestinal Hormones.

  2017cites this paper